CERO THERAPEUTICS HOLDINGS, INC.

CERO Therapeutics Holdings, Inc. (Nasdaq: CERO) is a clinical-stage biopharmaceutical company focused on engineered chimeric antigen receptor T-cell therapies targeting oncology indications. The company reached public markets through a special purpose acquisition company transaction and operates in the healthcare and biotechnology sector. On November 10, 2022, CERO Therapeutics Holdings filed a Form 10-Q with the SEC, accession number 0001193125-22-282566, reporting quarterly financial results and operational disclosures consistent with its obligations as a newly public entity. The filing reflects an early post-combination reporting period as the company advanced its cell-therapy pipeline toward clinical development. Visit SpacDesk and sign up for full data, filings history, and deal analytics on CERO and hundreds of other SPAC transactions.